This is a UK news story, published by Guardian, that relates primarily to The National Institute for Health and Care Excellence news.
For more UK news, you can click here:
more UK newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Guardian, you can click here:
more news from GuardianOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
obesity medication. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest tirzepatide news, semaglutide news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
more pharmacological optionsGuardian
•79% Informative
The National Institute for Health and Care Excellence has approved tirzepatide.
The drug, marketed in the UK as Mounjaro , is marketed as a more effective alternative to semaglutide.
Nice ’s move will probably increase the number of people taking obesity medication.
VR Score
74
Informative language
71
Neutral language
48
Article tone
formal
Language
English
Language complexity
64
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
2
Affiliate links
no affiliate links